Suzhou Ribo Life Science Co., Ltd. (SEHK: 6938)
Health Care · Biotechnology · CN
HK$52.90
+0.67% today · -35.6% 1Y
Suzhou Ribo Life Science Co., Ltd. (SEHK: 6938) operates in the Biotechnology industry within the Health Care sector. The company is valued at $1.15B and employs 407 people.
Over the last twelve months the share price has lost 35.6%, trading between 43.60 and 95.80.
Tweenvest scores Suzhou Ribo Life Science Co., Ltd. across four factors: quality 10/100. Its strongest factor is quality.
6938 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.15B
- Revenue (TTM)
- $21.23M
- P/E
- —
- EPS
- -2.11
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- HK$95.80
- 52-week low
- HK$43.60
- Avg volume (3M)
- —
- Shares outstanding
- 170.55M
- Employees
- 407
- Next earnings
- —
About Suzhou Ribo Life Science Co., Ltd.
Suzhou Ribo Life Science Co., Ltd. researches and develops novel therapeutics for the treatment of cardiovascular, metabolic, renal, and liver diseases in Chinese mainland and internationally. It develops RBD4059, which is phase 2 clinical trial for treating thrombotic diseases; RBD5044 that is in phase 2 clinical trial for treating hypertrigly ceridemia; RBD7022, which is in phase 2 clinical trial for the treatment of hypercho lesterolemia; RBD7007 and RBD2080 that are in Phase I clinical trial for the treatment of renal diseases; and RBD1119 for treating thrombotic diseases that is in Phase I clinical trial. The company also develops SR122 and SR126 for treating dyslipidemia; RBD3103 for treating renal diseases; RBD6096 for the treatment of thrombotic diseases; SR118 for treating metabolic diseases; RBD1016, which is in Phase II clinical trial for the treatment of CHB and CHD; RBD3133 for treating weight loss; RBD8088 for treating glioma; SR131 for treating CNS diseases; and SR111, SR112, and SR113 for the treatment of metabolic dysfunction-associated steatohepatitis. Suzhou Ribo Life Science Co., Ltd. was incorporated in 2007 and is based in Kunshan, China.
- ISIN
- CNE100007DS6
- Founded
- 2007
- Listed since
- Jan 9, 2026
- Exchange
- The Stock Exchange of Hong Kong Ltd.
- Currency
- HKD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $266.00 | +0.08% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $442.45 | +0.05% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.74 | -0.02% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $552.00 | -0.15% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $832.63 | -0.11% |
| argenx SEENXTBR: ARGX | $64.17B | €909.60 | +3.46% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $157.49 | -0.84% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.